Sanofi completes acquisition of Vigil Neuroscience, expands neurology pipeline.

Sanofi has completed its acquisition of Vigil Neuroscience, expanding its neurology pipeline with VG-3927, a TREM2 agonist for Alzheimer's disease. The deal includes Vigil's preclinical pipeline for various neurodegenerative diseases. Sanofi previously invested $40 million in Vigil in June 2024 with the right of first negotiation for an exclusive license. The acquisition strengthens Sanofi's research in neurodegenerative diseases.

Sanofi has completed its acquisition of Vigil Neuroscience, Inc., bolstering its neurology pipeline with VG-3927, a novel oral TREM2 agonist for Alzheimer's disease. The acquisition, finalized on August 6, 2025, also includes Vigil's preclinical pipeline for various neurodegenerative diseases. The deal reinforces Sanofi's research efforts in these critical areas.

In June 2024, Sanofi made a strategic investment of $40 million in Vigil, which included the exclusive right of first negotiation for an exclusive license to research, develop, manufacture, and commercialize VG-3927 [1]. Under the terms of the acquisition agreement, Sanofi acquired all outstanding common shares of Vigil for $8 per share in cash, representing an equity value of approximately $470 million on a fully diluted basis [2].

Additionally, Vigil's shareholders received a non-transferable contingent value right (CVR) per Vigil share, entitling them to a deferred cash payment of $2 upon the first commercial sale of VG-3927. The second clinical program, VGL101, was not included in the acquisition.

Sanofi's acquisition of Vigil Neuroscience is expected to enhance its research capabilities in neurodegenerative diseases. The company aims to leverage Vigil's preclinical pipeline to strengthen its overall research portfolio and potentially bring innovative therapies to market.

The acquisition does not impact Sanofi's financial guidance for 2025, as previously communicated [1]. Sanofi continues to focus on its mission of improving people’s lives through innovative medicines and vaccines, guided by its deep understanding of the immune system.

References:
[1] https://www.globenewswire.com/news-release/2025/08/06/3128014/0/fr/Communiqu%C3%A9-de-presse-Sanofi-finalise-l-acquisition-de-Vigil-Neuroscience-Inc.html
[2] https://www.globenewswire.com/news-release/2025/08/06/3128014/0/en/Press-Release-Sanofi-completes-the-acquisition-of-Vigil-Neuroscience-Inc.html